ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Achieving Timely Therapeutic Mycophenolic Acid Levels in Pediatric Lung Transplant Patients.

C. Kam, S. Kim, E. Melicoff.

Texas Children's Hospital, Houston, TX.

Meeting: 2016 American Transplant Congress

Abstract number: B286

Keywords: Dosage, Immunosuppression, Lung transplantation, Mycophenolate mofetil

Session Information

Date: Sunday, June 12, 2016

Session Name: Poster Session B: Lung Transplantation Posters

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Therapeutic Mycophenolic Acid Area-Under-Curve (MPA AUC) Levels Abolish Donor-Specific Antibody Formation in Established and De Novo Renal Transplant Patients
  • Prospective, 6 Month, Open Label, Conversion Study from Mycophenolate Mofetyl to Mycophenolic Acid Evaluating the Severity of Gastro-Intestinal Symptoms and Mycophenolic Acid Urinary Metabolite as a Surrogate Marker of Plasmatic Area Under the Curve

The purpose of this study was to determine the appropriate initial dose of mycophenolate mofetil (MMF) in pediatric cystic fibrosis (CF) and non-CF lung transplant recipients to achieve a therapeutic mycophenolic acid (MPA) level within 14 days post-transplant.

Methods: At the authors' institution, non-CF patients are initiated on MMF 600mg/m2 every 12 hours, and CF patients are initiated on MMF 800mg/m2 every 12 hours, and are titrated to an MPA trough of 1–3.5mcg/mL. A retrospective chart review was conducted on lung transplant recipients from January 1, 2013 through October 31, 2014. Patients were categorized as “Per Protocol” if the initial MMF dose was within ±100mg/m2 of the aforementioned doses. The time from transplantation to the first therapeutic MPA level was calculated, and the MMF dose in mg/m2 was documented.

Results: During the study period, 31 patients were transplanted. Table 1 summarizes the demographics and results for CF and non-CF patients.

 Table 1

CF

Non-CF

 

Total

Per Protocol

Not Per Protocol

Total

Per Protocol

Not Per Protocol

n (%)

11 (100)

7 (64)

4 (36)

20 (100)

11 (55)

9 (45)

Male (%)

6 (54)

–

–

6 (30)

–

–

Avg Age at Transplant (yr)

12.8

–

–

8.3

–

–

Avg Dose to Achieve 1st Therapeutic Level (mg/m2)

961

966

952

783

739

837

Avg Time in Days to Achieve 1st Therapeutic Level (range)

14.9

19 (10-28)

7.75 (4-11)

16.2

16.7 (4-41)

15.5 (4-30)

Number of Patients Therapeutic by 2 Weeks Post-Transplant (%)

7 (64%)

3 (43%)

4 (100%)

9 (45%)

5 (45%)

4 (44%)

Among CF patients, 71% of patients dosed per protocol required dose increases, compared to 0% among those who were not. Among non-CF patients, 45% of patients dosed per protocol required dose increases, compared to 33% among those who were not. Based on these results, in January 2015, the initial MMF dosing recommendation was increased by 100mg/m2 for both CF and non-CF lung transplant recipients. Since then, four CF patients and three non-CF patients have been transplanted. Six patients (86%) achieved a first therapeutic MPA level without dose adjustments. The average time to a therapeutic MPA level was six days.

Conclusions: In order to attain a therapeutic MPA level within 14 days post-lung transplant, non-CF patients may require an initial MMF dose of 700 mg/m2 every 12 hours, and CF patients may require an initial MMF dose of 900 mg/m2 every 12 hours.

CITATION INFORMATION: Kam C, Kim S, Melicoff E. Achieving Timely Therapeutic Mycophenolic Acid Levels in Pediatric Lung Transplant Patients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kam C, Kim S, Melicoff E. Achieving Timely Therapeutic Mycophenolic Acid Levels in Pediatric Lung Transplant Patients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/achieving-timely-therapeutic-mycophenolic-acid-levels-in-pediatric-lung-transplant-patients/. Accessed February 27, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.